Details for New Drug Application (NDA): 208026
✉ Email this page to a colleague
The generic ingredient in JENTADUETO XR is linagliptin; metformin hydrochloride. There are nineteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the linagliptin; metformin hydrochloride profile page.
Summary for 208026
Tradename: | JENTADUETO XR |
Applicant: | Boehringer Ingelheim |
Ingredient: | linagliptin; metformin hydrochloride |
Patents: | 9 |
Pharmacology for NDA: 208026
Mechanism of Action | Dipeptidyl Peptidase 4 Inhibitors |
Suppliers and Packaging for NDA: 208026
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
JENTADUETO XR | linagliptin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 208026 | NDA | Boehringer Ingelheim Pharmaceuticals, Inc. | 0597-0270 | 0597-0270-12 | 1 BOTTLE in 1 CARTON (0597-0270-12) / 14 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE |
JENTADUETO XR | linagliptin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 208026 | NDA | Boehringer Ingelheim Pharmaceuticals, Inc. | 0597-0270 | 0597-0270-73 | 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0597-0270-73) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 2.5MG;1GM | ||||
Approval Date: | May 27, 2016 | TE: | RLD: | Yes | |||||
Regulatory Exclusivity Expiration: | Dec 20, 2026 | ||||||||
Regulatory Exclusivity Use: | PEDIATRIC EXCLUSIVITY | ||||||||
Regulatory Exclusivity Expiration: | Jun 20, 2026 | ||||||||
Regulatory Exclusivity Use: | REVISIONS TO THE PEDIATRIC USE SUBSECTION OF LABELING TO INCLUDE THE RESULTS FROM CLINICAL STUDY 1218-0091, CONDUCTED TO FULFILL A PEDIATRIC WRITTEN REQUEST | ||||||||
Patent: | ⤷ Sign Up | Patent Expiration: | Oct 2, 2029 | Product Flag? | Substance Flag? | Delist Request? | Y |
Expired US Patents for NDA 208026
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Boehringer Ingelheim | JENTADUETO XR | linagliptin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 208026-002 | May 27, 2016 | ⤷ Sign Up | ⤷ Sign Up |
Boehringer Ingelheim | JENTADUETO XR | linagliptin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 208026-001 | May 27, 2016 | ⤷ Sign Up | ⤷ Sign Up |
Boehringer Ingelheim | JENTADUETO XR | linagliptin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 208026-002 | May 27, 2016 | ⤷ Sign Up | ⤷ Sign Up |
Boehringer Ingelheim | JENTADUETO XR | linagliptin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 208026-002 | May 27, 2016 | ⤷ Sign Up | ⤷ Sign Up |
Boehringer Ingelheim | JENTADUETO XR | linagliptin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 208026-002 | May 27, 2016 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription